Container1 (Container1)
Capecitabine Tablet
Product Images NDC 55111-497
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 55111-497). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Container2 (Container2)
Figure1 (Figure1)
Figure2 (Figure2)
Figure3 (Figure3)
This appears to be a table or chart. The heading mentions "Survival", with various year numbers listed in descending order. The row headings seem to refer to different treatments, including "5FU+ LEDCOVORN" and "CAPECITABNE". There are also groups with numbers and percentages listed. It may be related to a medical or scientific study.*
Figure4 (Figure4)
This appears to be a plot or graph of estimated probabilities over time for different treatment regimens including 5-FU and Capecitabine. The x-axis is labeled in days and the y-axis measures the probability of an outcome. Without additional context, it is difficult to provide more specific information.*
Figure5 (Figure5)
Figure6 (Figure6)
This appears to be a graph showing estimated probabilities for two different chemotherapy treatments, one using Docetaxel and Capecitabine together and another using Docetaxel alone. The probabilities are plotted on the y-axis and time (in days) on the x-axis. The graph shows that the combination treatment has higher estimated probability values than the Docetaxel alone treatment.*
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
